{"id":24936,"date":"2024-06-25T09:14:50","date_gmt":"2024-06-25T07:14:50","guid":{"rendered":"https:\/\/ggba.swiss\/?p=24936"},"modified":"2024-06-25T09:14:53","modified_gmt":"2024-06-25T07:14:53","slug":"ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/","title":{"rendered":"iOnctura secures EUR 80 million Series B financing to advance cancer treatments"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.ionctura.com\/\">iOnctura<\/a>, a clinical-stage biopharmaceutical company based in Geneva, announced it has closed an EUR 80 million Series B financing round. Led by <a href=\"https:\/\/www.synconaltd.com\/\">Syncona Limited<\/a>, with participation from the <a href=\"https:\/\/eic.ec.europa.eu\/eic-fund_en\">European Innovation Council Fund<\/a> and existing investors, this funding will accelerate the development of iOnctura\u2019s innovative cancer treatments.<\/p>\n\n\n\n<p>iOnctura is developing precision oral small molecules targeting neglected and hard-to-treat cancers. The company\u2019s lead asset, roginolisib, is the first allosteric modulator of PI3K\u03b4, showing promise in treating uveal melanoma and other oncology indications. Roginolisib has demonstrated an unprecedented clinical profile in solid and hematological malignancies, with over 48 patients treated to date.<\/p>\n\n\n\n<p>This financing will support the development of roginolisib for uveal melanoma, a rare eye cancer with limited treatment options, and expand its application to other cancers, including non-small cell lung cancer and primary myelofibrosis. Additionally, iOnctura\u2019s second clinical asset, cambritaxestat, an autotaxin inhibitor, is being developed for fibrotic tumors and is currently in a Phase Ib study for metastatic pancreatic cancer.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">A promising future for iOnctura\u2019s innovative approach<\/h4>\n\n\n\n<p>In the company\u2019s press release, Catherine Pickering, CEO of iOnctura, stated: \u201cThis financing validates iOnctura\u2019s approach to developing precision cancer treatments with maximum clinical impact. These therapies have the potential to significantly prolong the healthspan of patients suffering from neglected cancer types, such as uveal melanoma.\u201d<\/p>\n\n\n\n<p>Roel Bulthuis, Managing Partner at Syncona, added: \u201ciOnctura represents a compelling opportunity to invest in a clinical-stage company with a promising lead program. By allosterically modulating PI3K\u03b4, iOnctura has achieved a new level of precision and could be the first to develop a clinically meaningful medicine targeting this pathway.\u201d<\/p>\n\n\n\n<p>Previously, iOnctura received a <a href=\"https:\/\/ggba.swiss\/en\/the-fongit-innovation-fund-rewards-three-deeptech-start-ups\/\">growth loan of CHF 400,000 from the Fongit Innovation Fund<\/a>, highlighting its pioneering research and collaboration with esteemed partners. The company\u2019s continuous innovation aims to change the outlook for patients and their families, offering new hope through advanced cancer treatments.<\/p>\n\n\n\n<p>iOnctura\u2019s headquarters are in Amsterdam, with a wholly-owned subsidiary in Geneva, and it is backed by specialist institutional investors including Syncona, EIC Fund, <a href=\"https:\/\/www.m-ventures.com\/\">M Ventures<\/a>, <a href=\"https:\/\/www.inkef.com\/\">Inkef Capital<\/a>, <a href=\"https:\/\/www.vipartners.ch\/\">VI Partners<\/a>, and <a href=\"https:\/\/www.schroderscapital.com\/\">Schroders Capital<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>iOnctura has secured EUR 80 million in a Series B funding round to advance innovative cancer therapies, with a focus on neglected cancers such as uveal melanoma.<\/p>\n","protected":false},"author":6,"featured_media":24937,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[894,890,883,902,901],"class_list":["post-24936","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-financing","tag-healthcare","tag-oncology","tag-personalized-medicine","tag-technology-park"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>iOnctura secures EUR 80 million to advance cancer treatments<\/title>\n<meta name=\"description\" content=\"iOnctura has secured EUR 80 million to advance innovative cancer therapies, with a focus on neglected cancers such as uveal melanoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iOnctura secures EUR 80 million to advance cancer treatments\" \/>\n<meta property=\"og:description\" content=\"iOnctura has secured EUR 80 million to advance innovative cancer therapies, with a focus on neglected cancers such as uveal melanoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-25T07:14:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-25T07:14:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/iOnctura-Scientists-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"iOnctura secures EUR 80 million Series B financing to advance cancer treatments\",\"datePublished\":\"2024-06-25T07:14:50+00:00\",\"dateModified\":\"2024-06-25T07:14:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/\"},\"wordCount\":356,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/iOnctura-Scientists-1180x811-1.jpeg\",\"keywords\":[\"Financing\",\"Healthcare\",\"Oncology\",\"Personalized Medicine\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/\",\"url\":\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/\",\"name\":\"iOnctura secures EUR 80 million to advance cancer treatments\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/iOnctura-Scientists-1180x811-1.jpeg\",\"datePublished\":\"2024-06-25T07:14:50+00:00\",\"dateModified\":\"2024-06-25T07:14:53+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"iOnctura has secured EUR 80 million to advance innovative cancer therapies, with a focus on neglected cancers such as uveal melanoma.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/iOnctura-Scientists-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/iOnctura-Scientists-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"iOnctura\u2019s mission is to develop high-impact, low-disruption therapies that extend healthspan, which is achieved this by targeting and disrupting the dynamic interplay at the tumor-stroma-immune interface. | \u00a9 iOnctura\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iOnctura secures EUR 80 million Series B financing to advance cancer treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iOnctura secures EUR 80 million to advance cancer treatments","description":"iOnctura has secured EUR 80 million to advance innovative cancer therapies, with a focus on neglected cancers such as uveal melanoma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/","og_locale":"en_US","og_type":"article","og_title":"iOnctura secures EUR 80 million to advance cancer treatments","og_description":"iOnctura has secured EUR 80 million to advance innovative cancer therapies, with a focus on neglected cancers such as uveal melanoma.","og_url":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-06-25T07:14:50+00:00","article_modified_time":"2024-06-25T07:14:53+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/iOnctura-Scientists-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"iOnctura secures EUR 80 million Series B financing to advance cancer treatments","datePublished":"2024-06-25T07:14:50+00:00","dateModified":"2024-06-25T07:14:53+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/"},"wordCount":356,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/iOnctura-Scientists-1180x811-1.jpeg","keywords":["Financing","Healthcare","Oncology","Personalized Medicine","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/","url":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/","name":"iOnctura secures EUR 80 million to advance cancer treatments","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/iOnctura-Scientists-1180x811-1.jpeg","datePublished":"2024-06-25T07:14:50+00:00","dateModified":"2024-06-25T07:14:53+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"iOnctura has secured EUR 80 million to advance innovative cancer therapies, with a focus on neglected cancers such as uveal melanoma.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/iOnctura-Scientists-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/iOnctura-Scientists-1180x811-1.jpeg","width":1180,"height":811,"caption":"iOnctura\u2019s mission is to develop high-impact, low-disruption therapies that extend healthspan, which is achieved this by targeting and disrupting the dynamic interplay at the tumor-stroma-immune interface. | \u00a9 iOnctura"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/ionctura-secures-eur-80-million-series-b-financing-to-advance-cancer-treatments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"iOnctura secures EUR 80 million Series B financing to advance cancer treatments"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=24936"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24936\/revisions"}],"predecessor-version":[{"id":24940,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24936\/revisions\/24940"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/24937"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=24936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=24936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=24936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}